Effect of ribavirin aerosol on viral infection of upper respiratory tract in children: a multicenter clinical observation

HONG Jian-guo,LI Zhen,CAO Lan-fang,CHEN Pei-li,WANG Li-bo,BAO Yi-xiao,GU Hong-liang

DOI: https://doi.org/10.3969/j.issn.1000-3606.2006.06.036

2006-01-01

Abstract:Objective To evaluate the efficacy and safety of ribavirin aerosol on viral infection of upper respiratory tract. Methods A randomized, open lable, parallel, controlled trial was performed. A total of 176 children with viral upper respiratory tract infection were randomized to receive either ribavirin aerosol(n=87) or ribavirin granules (n=89). There were no differences on gender, age, height, and clini-cal manifestation between two groups. In ribavirin aerosol group, medication was given for four times within first hour, followed by every two hours for the remaining time of the day and day 2. From day 3 to day 5, it was given for 4 times per day. In ribavirin granules group, medication was given at the dosage of 15mg/(kg·d), and divided into 3 times for 5 days. Results There were no significant differences in the improvement of fever and cold symptoms (cough, catarrhus and malaise) between two groups after the treatment. But significant improvement was seen from day 2 when comparison was made within these two groups (p<0.05) with no significantly difference in the incidence of GI and local irritation symptoms and no notable decrease of complete blood count. Conclusion Ribavirin aerosol could be effectively and safelyused for treating viral infection of upper respiratory tract in children with lower dosage. The daily dose of ribavirin aerosol was much less than a twentieth of oral ribavirin granules dosage. The aerosol could easily reach oropharynx in high concentration with quicker action and fewer side effects. A conception of therapy without injection and oral ribavirin aerosol as a first line choice for common cold treatment were proposed.